The Foundayo evidence supports a prescribing discussion, not a guaranteed percentage or a universal league table. Read every result with its population, formulation, comparator, duration and analysis.
Start with the question the trial asked
ATTAIN-1 compared orforglipron with placebo in adults with obesity, or overweight with a weight-related condition, who did not have diabetes. Participants received lifestyle support and gradual dose escalation. The trial therefore tested the treatment as part of an organised programme rather than a tablet used without follow-up.
In the treatment-regimen analysis, average weight reductions at 72 weeks were 7.5%, 8.4% and 11.2% across the research-dose groups, versus 2.1% with placebo. The study used capsule strengths that differ from the marketed UK tablets. Keep those details beside the figures rather than presenting a number as the expected result of any Foundayo prescription.
Ask who is included in a headline average
Clinical reports may present more than one analysis. An analysis considering the assigned treatment strategy, including discontinuation, answers a different question from an estimate focused on treatment taken as intended. A larger percentage is not automatically a more relevant prediction for someone considering treatment in everyday life.
When two articles quote different figures, check their analysis labels before assuming one is wrong. Also look for the number of participants, the endpoint date and how missing measurements were handled. You do not need to reproduce the statistics to recognise that the headline alone is insufficient.
Sources: New England Journal of Medicine: ATTAIN-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment; Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026
Diabetes changes which evidence is most relevant
ATTAIN-2 enrolled people with type 2 diabetes. At 72 weeks, its treatment-regimen analysis reported mean reductions of 5.1%, 7.0% and 9.6% across the research-dose groups, compared with 2.5% with placebo. These results should be described as a separate study, not merged with ATTAIN-1 into one universal expected loss.
If you have diabetes, ask the clinician to explain both the weight-management objective and the glucose-management plan. Another diabetes medicine may need review. A discussion confined to kilograms can miss the reason treatment is being selected and the monitoring needed to use it safely.
Sources: The Lancet / PubMed: ATTAIN-2: Orforglipron for obesity in people with type 2 diabetes; Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet
Benefit and tolerability belong in the same account
The trials reported gastrointestinal adverse events, and some participants discontinued because of adverse effects. A comparison that reports only average weight loss omits a meaningful part of the experience. Ask what support the provider offers when symptoms interfere with normal intake or when dose progression is not manageable.
Do not interpret a study's 'generally mild or moderate' description as a judgement about your own symptoms. Those are aggregate trial classifications. Your assessment should consider severity, persistence and the effect on daily life. Serious or rapidly worsening symptoms need care, not a comparison with the average participant.
Sources: New England Journal of Medicine: ATTAIN-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment; Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet
Use the evidence to ask better personal questions
A placebo-controlled trial cannot by itself rank Foundayo against every injection or oral semaglutide. Differences in participants, duration and analysis make informal cross-trial comparisons uncertain. A direct comparison, when available for a particular question, still applies to the doses and population actually studied.
Bring the decision back to your own circumstances: which health problem is being addressed, what routine is feasible, which interactions require attention and how continuing care will be funded. Agree a review point and measures of benefit. That gives the evidence a concrete role without asking it to predict an individual outcome it cannot guarantee.
Sources: MHRA: UK authorises orforglipron for weight management and type 2 diabetes; NICE: Overweight and obesity management: medicines and surgery; Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026
Questions, answered.
Does an 11.2% average mean I should expect exactly that?
No. It is a group result from a particular study and analysis. Individual outcomes vary.
Can I use the research capsule strengths to choose tablets?
No. Use the marketed UK tablet prescription. Research and marketed formulations have different labelled strengths.
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- ATTAIN-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentNew England Journal of Medicine · Accessed 19 November 2026
- ATTAIN-2: Orforglipron for obesity in people with type 2 diabetesThe Lancet / PubMed · Accessed 19 November 2026
- Foundayo: UK Summary of Product Characteristics, revised 3 November 2026Eli Lilly / electronic medicines compendium · Accessed 19 November 2026
- Foundayo: patient information leafletEli Lilly / electronic medicines compendium · Accessed 19 November 2026
- UK authorises orforglipron for weight management and type 2 diabetesMHRA · Accessed 19 November 2026
- Overweight and obesity management: medicines and surgeryNICE · Accessed 19 November 2026
